Mesenchymal Stem Cell Therapy in Severe COVID-19 in a Young Male Healthcare Worker with Tetralogy of Fallot
| Autor: | YÜKSEL, Recep Civan, EREN, Esma, ULU KILIÇ, Ayşegül, ÇELİK, İlhami |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Volume: 7, Issue: 1 26-30 Journal of Anatolian Medical Research |
| ISSN: | 2587-1153 |
| Popis: | A novel type of coronavirus (SARS-CoV-2), which causesevere acute respiratory syndrome, wasfirst identified in Wuhan,China at the end of December 2019 and the disease rapidly spread worldwide. COVID-19 may be characterized by arange of symptoms, mild illness to severe pneumoniae. Cardiovascular diseases increase severity and mortality in COVID-19patients. Tetralogy of Fallot is the most common cyanotic congenital heart disease. The present case is an adult COVID-19patient with a history of Tetralogy of Fallot, who is a healthcare worker. High Flow Nasal Oxygen therapy was used due torespiratory distress. In addition, Mesenchymal Stem Cells were applied while the disease was in critical process. The clinicaland laboratory improvement were observed in the patient from the second day of treatment of Mesenchymal Stem Cells. Theyoung healthcare worker with a history of Tetralogy of Fallot needed critical care due to COVID-19. Response to the antiviraltreatments given to the patient could not be obtained. High Flow Nasal Oxygen and Mesenchymal Stem Cells were used inthe treatment of the patient. Background: A novel type of coronavirus (SARS- CoV -2), which cause severe acute respiratory syndrome, was first identified in Wuhan, China at the end of December 2019 and the disease rapidly spread worldwide. COVID-19 may be characterized by a range of symptoms; mild illness to severe pneumoniae. Cardiovascular diseases increase severity and mortality in COVID-19 patients. Tetralogy of Fallot (ToF) is the most common cyanotic congenital heart disease. Case presentation: Present case is an adult COVID-19 patient with a history of ToF, who is a healthcare worker. High Flow Nasal Oxygen (HFNO) was used due to respiratory distress. In addition, Mesenchymal Stem Cells (MSCs) were applied while the disease was in critical process. Clinical and laboratory improvement was observed in the patient from the second day of treatment of MSCs.Conclusions: The young healthcare worker with a history of ToF needed critical care due to COVID-19. Response to the antiviral treatments given to the patient could not be obtained. HFNO and MSCs were used in the treatment of the patient. Clinical and laboratory improvement was observed in the patient from the second day of treatment of MSCs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|